Cingulate (CING) announced positive top-line results from the CTx-1301-013 study, an FDA required study, assessing the effect of food on absorption of the highest dose of its lead candidate CTx-1301. CTx-1301 is a novel, investigational, trimodal, extended-release tablet formulation of dexmethylphenidate, a compound approved by the U.S. Food and Drug Administration for the treatment of Attention Deficit/Hyperactivity Disorder. The trial demonstrated that 50mg CTx-1301 can be taken with or without food. Multiple pharmacokinetic measurements were taken, and adverse events were consistent with previous findings and indicate a favorable tolerability profile.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CING:
- Cingulate Inc Secures $3M Grant for Anxiety Drug
- Cingulate receives $3M grant from to accelerate development of CTx-2103
- Cingulate Inc’s Strategic Progress and Promising Clinical Results Justify Buy Rating
- Cingulate completes pre-NDA meeting with FDA on NDA for CTx-1301
- Cingulate Inc. Reports 2024 Financial and Development Milestones